Brief: Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting
07/03/2025 06:03
March 7 (Reuters) - argenx SE ARGX.BR: ARGENX HIGHLIGHTS FCRN LEADERSHIP WITH LONG-TERM DATA AND TRANSFORMATIONAL PATIENT OUTCOMES AT THE AMERICAN ACADEMY OF NEUROLOGY 2025 ANNUAL MEETING LARGEST SAFETY DATA SET SHOWS FAVORABLE PROFILE FOR VYVGART Source text: nGNE6xkKqm Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles